Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMpact2; KEEPsAKE 2
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 03 Jun 2023 Results of post-hoc analysis of two studies KEEPsAKE 1 and 2 assessing improvements in patient-reported outcomes, presented at the 24th Annual Congress of the European League Against Rheumatism.
  • 03 Jun 2023 Results of pooled analysis from KEEPsAKE 1 and 2, assessing the durability of the RZB treatment response on health-related quality of life (HRQoL) and patient-reported outcomes (PROs) in patients with PsA at Week 100, presented at the 24th Annual Congress of the European League Against Rheumatism
  • 03 Jun 2023 Results (n=707 from studies KEEPsAKE 1 and KEEPsAKE 2 ) assessing response rates in PsA patients with limited (5 to 8) and extensive (more than 9) swollen joint after treatment with RZB to examine whether its efficacy differed according to the extent of joint involvement presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top